Opaleye Management Inc.
In its 13F for Q2 2024 (holdings as of June 30, 2024, filed August 14, 2024), Opaleye Management Inc. reported 49 stock positions worth $430.0 million. Its top holding was Harrow (HROW) at 19.4% of the portfolio, followed by TG Therapeutics (TGTX, 9.4%) and Ocular Therapeutix (OCUL, 8.4%). Compared with Q1 2024, it opened 9 new positions, sold out of 11, added to 15 and reduced 17. The biggest buy was Harrow (HROW, shares +2%) and the biggest sale Ocular Therapeutix (OCUL, shares −20%).
- Most Recent 13F
- Q2 2026
- Location
- BOSTON, MA
- CIK
- 0001595855
- Portfolio Value
- $430.0M (Q2 2024)
- SEC Filing
- 0001493152-24-032150 ↗ filed Aug 14, 2024
Holdings Value
Holdings 49 stocks · $430.0M
| HROW Harrow Inc. | 19.39% | 3,990,000 | $83.4M | Add +1.8% |
| TGTX TG Therapeutics Inc. | 9.43% | 2,280,000 | $40.6M | No change |
| OCUL Ocular Therapeutix Inc. | 8.44% | 5,307,500 | $36.3M | Reduce -20.2% |
| RYTM Rhythm Pharmaceuticals Inc. | 4.92% | 515,000 | $21.1M | No change |
| KROS Keros Therapeutics Inc. | 3.91% | 367,500 | $16.8M | No change |
| ARVN Arvinas Inc. | 3.44% | 555,000 | $14.8M | Add +68.2% |
| IMNM Immunome Inc. | 3.10% | 1,102,500 | $13.3M | New |
| CYTK Cytokinetics Inc. | 2.50% | 198,500 | $10.8M | New |
| CDXS Codexis Inc. | 2.49% | 3,455,000 | $10.7M | Add +10.7% |
| EWTX Edgewise Therapeutics Inc. | 2.43% | 580,000 | $10.4M | Reduce -12.8% |
| CPRX Catalyst Pharmaceuticals Inc. | 2.31% | 640,000 | $9.9M | Reduce -36.3% |
| CRGX Cargo Therapeutics Inc. | 2.12% | 555,700 | $9.1M | New |
| JSPR Jasper Therapeutics Inc. | 2.07% | 392,000 | $8.9M | Reduce -10.0% |
| NRIX Nurix Therapeutics Inc. | 2.03% | 418,928 | $8.7M | Add +56.8% |
| TRVI Trevi Therapeutics Inc. | 1.83% | 2,645,000 | $7.9M | No change |
| ETON Eton Pharmaceuticals Inc. | 1.83% | 2,395,000 | $7.9M | Reduce -2.1% |
| APLT Applied Therapeutics Inc. | 1.82% | 1,680,000 | $7.8M | Reduce -5.1% |
| FDMT 4D Molecular Therapeutics Inc. | 1.69% | 345,750 | $7.3M | Add +0.5% |
| IOVA Iovance Biotherapeutics Inc. | 1.67% | 897,000 | $7.2M | No change |
| SLRN Acelyrin Inc. | 1.62% | 1,580,000 | $7.0M | No change |
| URGN Urogen Pharma Ltd. | 1.61% | 412,000 | $6.9M | Add +52.6% |
| PCVX Vaxcyte Inc. | 1.49% | 85,000 | $6.4M | No change |
| BDSX Biodesix Inc. | 1.43% | 4,020,000 | $6.2M | Add +651.9% |
| NAMS Newamsterdam Pharma Co. NV | 1.41% | 315,000 | $6.1M | Reduce -0.1% |
| XOMA Xoma Royalty Corporation filed as XOMA CORP DEL | 1.38% | 250,000 | $5.9M | No change |
| TARA Protara Therapeutic Inc. | 1.23% | 2,304,262 | $5.3M | Reduce -14.4% |
| NTLA Intellia Therapeutics Inc. | 1.13% | 218,000 | $4.9M | Reduce -14.5% |
| NUVL Nuvalent Inc. Class A | 1.05% | 59,300 | $4.5M | New |
| SYRS Syros Pharmaceuticals Inc. | 1.04% | 865,443 | $4.5M | Add +9.9% |
| LQDA Liquidia Corp. | 0.91% | 325,000 | $3.9M | Reduce -17.7% |
| PTGX Protagonist Therapeutics Inc. | 0.85% | 105,000 | $3.6M | Reduce -6.8% |
| GOSS Gossamer Bio Inc. | 0.82% | 3,910,000 | $3.5M | Add +60.2% |
| LXRX Lexicon Pharmaceuticals Inc. | 0.73% | 1,875,000 | $3.1M | New |
| SVRA Savara Inc. | 0.67% | 714,960 | $2.9M | Reduce -16.4% |
| ALLK Allakos LLC | 0.65% | 2,780,000 | $2.8M | Add +14.2% |
| VTYX Ventyx Biosciences Inc. | 0.64% | 1,190,000 | $2.7M | Reduce -7.4% |
| VSTM Verastem Inc. | 0.63% | 915,000 | $2.7M | Add +332.8% |
| RGLS Regulus Therapeutics Inc. | 0.61% | 1,475,000 | $2.6M | Add +766.1% |
| LYEL Lyell Immunopharma Inc. | 0.56% | 1,670,000 | $2.4M | Reduce -50.2% |
| RLMD Relmada Therapeutics Inc. | 0.42% | 600,000 | $1.8M | Reduce -20.9% |
| FULC Fulcrum Therapeutics Inc. | 0.41% | 285,000 | $1.8M | Add +119.2% |
| KPTI Karyopharm Therapeutics Inc. | 0.29% | 1,425,000 | $1.2M | New |
| IBIO Ibio Inc. | 0.18% | 375,000 | $791K | Reduce -44.9% |
| PMVP PMV Pharmaceuticals Inc. | 0.18% | 475,000 | $770K | Add +0.8% |
| AEROVATE THERAPEUTICS INC | 0.17% | 440,000 | $730K | New |
| DSGN Design Therapeutics Inc. | 0.16% | 205,000 | $687K | Add +81.3% |
| ABCL Abcellera Biologics Inc. | 0.14% | 200,000 | $592K | New |
| ALGS Aligos Therapeutics Inc. | 0.10% | 1,260,000 | $441K | Reduce -22.7% |
| RENEO PHARMACEUTICALS INC | 0.06% | 165,000 | $249K | New |
Other holdings (2): bonds, preferreds, convertibles and warrants · $7.7M (not counted above)
| Security | Class | Shares / Principal | Value | Change |
|---|---|---|---|---|
| GOSSAMER BIO INC (GOSS 5 06/01/27) | NOTE 5.000% 6/0 · principal | 8,000,000 | $4.0M | No change |
| KARYOPHARM THERAPEUTICS (KPTI 3 10/15/25) | NOTE 3.000%10/1 · principal | 6,000,000 | $3.7M | New |
Total filed on the 13F, all lines: $437.7M.
Portfolio Sells Q1 2024 → Q2 2024
| OCUL Ocular Therapeutix Inc. | Reduce -20.2% | 8.44% | −4.84 |
| CRNX Crinetics Pharmaceuticals Inc. | Sold out | 0.00% | −2.16 |
| CMPX Compass Therapeutics Inc. | Sold out | 0.00% | −1.38 |
| CPRX Catalyst Pharmaceuticals Inc. | Reduce -36.3% | 2.31% | −1.21 |
| TARA Protara Therapeutic Inc. | Reduce -14.4% | 1.23% | −1.14 |
| LYEL Lyell Immunopharma Inc. | Reduce -50.2% | 0.56% | −1.08 |
| NYXH Nyxoah SA | Sold out | 0.00% | −0.95 |
| VTYX Ventyx Biosciences Inc. | Reduce -7.4% | 0.64% | −0.91 |
| RVNC Revance Therapeutics Inc. | Sold out | 0.00% | −0.85 |
| APLT Applied Therapeutics Inc. | Reduce -5.1% | 1.82% | −0.82 |
| JSPR Jasper Therapeutics Inc. | Reduce -10.0% | 2.07% | −0.74 |
| ZNTL Zentalis Pharmaceuticals Inc. | Sold out | 0.00% | −0.69 |
| IBIO Ibio Inc. | Reduce -44.9% | 0.18% | −0.42 |
| NTLA Intellia Therapeutics Inc. | Reduce -14.5% | 1.13% | −0.40 |
| LQDA Liquidia Corp. | Reduce -17.7% | 0.91% | −0.37 |
| RLMD Relmada Therapeutics Inc. | Reduce -20.9% | 0.42% | −0.36 |
| CNTX Context Therapeutics Inc. | Sold out | 0.00% | −0.34 |
| PGEN Precigen Inc. | Sold out | 0.00% | −0.30 |
| LRMR Larimar Therapeutics Inc. | Sold out | 0.00% | −0.29 |
| SVRA Savara Inc. | Reduce -16.4% | 0.67% | −0.26 |
| MOR Morphosys AG ADR | Sold out | 0.00% | −0.26 |
| ALGS Aligos Therapeutics Inc. | Reduce -22.7% | 0.10% | −0.25 |
| EWTX Edgewise Therapeutics Inc. | Reduce -12.8% | 2.43% | −0.23 |
| NAMS Newamsterdam Pharma Co. NV | Reduce -0.1% | 1.41% | −0.23 |
| ETON Eton Pharmaceuticals Inc. | Reduce -2.1% | 1.83% | −0.18 |
| GKOS Glaukos Corp. | Sold out | 0.00% | −0.18 |
| RPTX Repare Therapeutics Inc. | Sold out | 0.00% | −0.07 |
| PTGX Protagonist Therapeutics Inc. | Reduce -6.8% | 0.85% | +0.13 |
Portfolio Buys Q1 2024 → Q2 2024
| HROW Harrow Inc. | Add +1.8% | 19.39% | +8.00 |
| IMNM Immunome Inc. | New | 3.10% | +3.10 |
| CYTK Cytokinetics Inc. | New | 2.50% | +2.50 |
| CRGX Cargo Therapeutics Inc. | New | 2.12% | +2.12 |
| BDSX Biodesix Inc. | Add +651.9% | 1.43% | +1.26 |
| NRIX Nurix Therapeutics Inc. | Add +56.8% | 2.03% | +1.17 |
| NUVL Nuvalent Inc. Class A | New | 1.05% | +1.05 |
| LXRX Lexicon Pharmaceuticals Inc. | New | 0.73% | +0.73 |
| URGN Urogen Pharma Ltd. | Add +52.6% | 1.61% | +0.72 |
| RGLS Regulus Therapeutics Inc. | Add +766.1% | 0.61% | +0.50 |
| ARVN Arvinas Inc. | Add +68.2% | 3.44% | +0.45 |
| KPTI Karyopharm Therapeutics Inc. | New | 0.29% | +0.29 |
| GOSS Gossamer Bio Inc. | Add +60.2% | 0.82% | +0.19 |
| AEROVATE THERAPEUTICS INC | New | 0.17% | +0.17 |
| FULC Fulcrum Therapeutics Inc. | Add +119.2% | 0.41% | +0.14 |
| ABCL Abcellera Biologics Inc. | New | 0.14% | +0.14 |
| SYRS Syros Pharmaceuticals Inc. | Add +9.9% | 1.04% | +0.11 |
| CDXS Codexis Inc. | Add +10.7% | 2.49% | +0.10 |
| VSTM Verastem Inc. | Add +332.8% | 0.63% | +0.09 |
| DSGN Design Therapeutics Inc. | Add +81.3% | 0.16% | +0.06 |
| RENEO PHARMACEUTICALS INC | New | 0.06% | +0.06 |
| PMVP PMV Pharmaceuticals Inc. | Add +0.8% | 0.18% | +0.00 |
| ALLK Allakos LLC | Add +14.2% | 0.65% | −0.03 |
| FDMT 4D Molecular Therapeutics Inc. | Add +0.5% | 1.69% | −0.72 |
Notes & Other Activity Q1 2024 → Q2 2024
| KARYOPHARM THERAPEUTICS (KPTI 3 10/15/25) | NOTE 3.000%10/1 · principal | New | 6,000,000 | $3.7M |
Bonds, preferreds, convertibles and warrants; not part of the stock holdings or percentages above.
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 58 | $1.1B | LQDA, ETON, HROW, IRON, URGN |
| Q1 2026 | 54 | $759.2M | HROW, LQDA, ETON, SLGL, RYTM |
| Q4 2025Amended | 54 | $757.9M | HROW, LQDA, ETON, RYTM, APGE |
| Q3 2025 | 42 | $702.7M | HROW, ETON, LQDA, RYTM, IMNM |
| Q2 2025Amended | 39 | $483.6M | HROW, ETON, IMNM, SNWV, LQDA |
| Q1 2025 | 43 | $438.3M | HROW, ETON, SNWV, LQDA, RYTM |
| Q4 2024 | 37 | $560.7M | HROW, TGTX, CDXS, ETON, OCUL |
| Q3 2024 | 42 | $591.4M | HROW, TGTX, OCUL, ARVN, CDXS |
| Q2 2024 | 49 | $430.0M | HROW, TGTX, OCUL, RYTM, KROS |
| Q1 2024Amended | 51 | $455.6M | OCUL, HROW, TGTX, KROS, RYTM |